NAMD Comments on 340B Ceiling Price Rule

NAMD provided written comments to the Health Resources and Services Administration on its proposed rule addressing ceiling prices and manufacturer civil monetary penalties in the 340B drug discount program.

Read the full letter here.

Comments are closed.